3SBio Sees Strong Growth In Q1 Driven By Oncology Product EPIAO
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Biotech company 3SBio saw revenues increase 23.7 percent in the first quarter of 2009, driven by the company's leading recombinant human erythropoietin injection EPIAO, the only approved EPO drug in China